tiprankstipranks
Advertisement
Advertisement

ARQT Stock Latest News

Oruka Therapeutics appoints Todd Edwards as chief commercial officer
The FlyOruka Therapeutics appoints Todd Edwards as chief commercial officer
9h ago
ARQT
ORKA
Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis
PremiumCompany Announcements
Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis
4d ago
ARQT
Arcutis says Health Canada approves Zoryve cream 0.05% for children with AD
PremiumThe Fly
Arcutis says Health Canada approves Zoryve cream 0.05% for children with AD
4d ago
ARQT
Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study
PremiumCompany Announcements
Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study
12d ago
ARQT
Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum
PremiumCompany Announcements
Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum
13d ago
ARQT
Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley
PremiumThe FlyArcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley
19d ago
ARQT
Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho
Premium
The Fly
Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho
19d ago
ARQT
Arcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim
Premium
The Fly
Arcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim
19d ago
ARQT
Arcutis (ARQT): Strong Zoryve Outperformance and Raised 2026 Sales Outlook Underscore Buy Rating
PremiumRatings
Arcutis (ARQT): Strong Zoryve Outperformance and Raised 2026 Sales Outlook Underscore Buy Rating
19d ago
ARQT
Arcutis Biotherapeutics Announces Key Commercial Leadership Changes
PremiumCompany Announcements
Arcutis Biotherapeutics Announces Key Commercial Leadership Changes
19d ago
8K
ARQT
Arcutis Biotherapeutics reports Q2 EPS 11c, consensus 5c
PremiumThe Fly
Arcutis Biotherapeutics reports Q2 EPS 11c, consensus 5c
19d ago
ARQT
Arcutis Biotherapeutics raises FY26 revenue view to $525M-$540M from $480M-$495M
PremiumThe Fly
Arcutis Biotherapeutics raises FY26 revenue view to $525M-$540M from $480M-$495M
19d ago
ARQT
Arcutis Biotherapeutics Adds Veteran Director to Board
PremiumCompany AnnouncementsArcutis Biotherapeutics Adds Veteran Director to Board
1M ago
8K
ARQT
Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board
Premium
The Fly
Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board
1M ago
ARQT
MIRM
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
Premium
The Fly
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
2M ago
ARQT
Arcutis Buy Rating Reaffirmed as Zoryve Pediatric Label Expansion Supports Long-Term Growth; Price Target Maintained at $36
PremiumRatings
Arcutis Buy Rating Reaffirmed as Zoryve Pediatric Label Expansion Supports Long-Term Growth; Price Target Maintained at $36
2M ago
ARQT
FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream
PremiumThe Fly
FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream
2M ago
ARQT
Arcutis Stockholders Approve Proposals at 2026 Meeting
PremiumCompany Announcements
Arcutis Stockholders Approve Proposals at 2026 Meeting
3M ago
8K
ARQT
Arcutis Earnings Call Signals Momentum Amid Headwinds
PremiumCompany Announcements
Arcutis Earnings Call Signals Momentum Amid Headwinds
4M ago
ARQT
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
PremiumThe FlyArcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
4M ago
ARQT
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
Premium
Ratings
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
4M ago
ARQT
Analyst Reiterates Buy on Arcutis as Zoryve Momentum, New Data Support Unchanged $34 Price Target
Premium
Ratings
Analyst Reiterates Buy on Arcutis as Zoryve Momentum, New Data Support Unchanged $34 Price Target
4M ago
ARQT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >